Pharma BD Deal Intelligence
Daiichi Sankyo Company, Limited / Nosis Biosciences, Inc.
2025 · Licensing/Option · Complete
Nosis Biosciences entered a research collaboration and option agreement with Daiichi Sankyo to develop cell-targeted RNA medicines using Nosis' Connexa platform, an AI-driven drug design and delivery system intended to enable gene silencing in extrahepatic cell types including heart, brain, lung, kidney and muscle. Financial terms were not disclosed.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.
Key facts
- Announced Mar 11, 2025
- Deal type Licensing/Option
- Therapeutic area Multiple (chronic diseases)
- Key assets Option rights to RNA therapeutic candidates from the Nosis Connexa platform
- Mechanism Cell-targeted RNA silencing via Connexa delivery platform
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2025 deals · Daiichi Sankyo Company, Limited deals